MENU
DGX
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

DGX stock forecast, quote, news & analysis

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US... Show more

DGX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for DGX with price predictions
Jul 31, 2026

Momentum Indicator for DGX turns positive, indicating new upward trend

DGX saw its Momentum Indicator move above the 0 level on July 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for DGX just turned positive on July 23, 2026. Looking at past instances where DGX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DGX advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 291 cases where DGX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DGX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DGX broke above its upper Bollinger Band on July 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. DGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.422) is normal, around the industry mean (69.994). P/E Ratio (24.736) is within average values for comparable stocks, (159.234). Projected Growth (PEG Ratio) (1.944) is also within normal values, averaging (1.659). DGX has a moderately high Dividend Yield (0.014) as compared to the industry average of (0.007). P/S Ratio (2.268) is also within normal values, averaging (8.241).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Dividends

DGX paid dividends on July 22, 2026

Quest Diagnostics DGX Stock Dividends
А dividend of $0.86 per share was paid with a record date of July 22, 2026, and an ex-dividend date of July 08, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 17.45B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 0%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 7%. CDNA experienced the highest price growth at 18%, while MYGN experienced the biggest fall at -49%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 50%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 66
Price Growth Rating: 46
SMR Rating: 80
Profit Risk Rating: 91
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
DGX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of diagnostic testing and information services

Industry MedicalSpecialties

Profile
Details
Industry
Servicestothe Health Industry
Address
500 Plaza Drive
Phone
+1 973 520-2700
Employees
48000
Web
https://www.questdiagnostics.com
Momentum Indicator for DGX turns positive, indicating new upward trend